Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Look up the active ingredients in the supplement
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
A polymorphism or variation in the sequence within an ER-response element located in the SELENOS promoter was found to result in reduced SELENOS promoter activity and gene expression (36)
Backed by the National Institute on Aging (NIA), the Texas A&M team pooled collaborative knowledge, expertise and resources to turn a simple nasal spray into a therapy with the potential to reframe how scientists think about brain aging
A 2023 Cochrane review found that Cerebrolysin provided no clear benefit for preventing death in acute ischemic stroke, and noted a potentially higher rate of spontaneous adverse events in some trial subgroups
US$ 25.46
US$ 25.35
US$ 22.30
US$ 25.58
US$ 24.74
US$ 22.17
US$ 22.53
US$ 26.44